Cargando…
The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
INTRODUCTION: Proximal tubule sodium uptake is diminished following sodium glucose cotransporter 2 (SGLT2) inhibition. We previously showed that during SGLT2 inhibition, the kidneys adapt by increasing sodium uptake at distal tubular segments, thereby maintaining body sodium balance. Despite continu...
Autores principales: | Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Hammarstedt, Ann, Karlsson, Cecilia, Hallow, Karen M., Danser, A.H. Jan, Heerspink, Hiddo J.L., van Raalte, Daniël H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091605/ https://www.ncbi.nlm.nih.gov/pubmed/35570989 http://dx.doi.org/10.1016/j.ekir.2022.02.023 |
Ejemplares similares
-
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021) -
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
por: Sen, Taha, et al.
Publicado: (2022) -
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023) -
The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
por: Scholtes, Rosalie A., et al.
Publicado: (2019) -
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)